OIP5 and plasma cell myeloma: We designed a panel of CTA candidates previously shown to be expressed in colorectal cancer (MAGEA1, A2, and A3; OIP5; PLAC1; CAGE; SSX4; HAGE; NY-ESO-1; and FBXO39) [17–20] and included some promising new targets (CAGE1, TTK, CXorf48, KU-CT-1, PLU1, LDHC, DKKL1, and RGS22), which are expressed in lung cancer, multiple myeloma, esophageal squamous cell carcinoma, breast cancer, melanoma, and head and neck squamous cell carcinoma [21–23].